The functions and efficacy of Naxitamab injection

Naxitamab injection (Naxitamab) is a humanized monoclonal antibody directed against disialoganglioside GD2. Nocertuzumab injection can be used in the research of neuroblastoma, osteosarcoma and other GD2-positive cancers. Noxetuzumab injection is approved for the treatment of neuroblastoma in the bone marrow and/or bone with a high degree of refractory or risk of recurrence, thanks to impressive results and their duration in an incurable patient population.

This treatment was invented at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, USA, and developed by Ymabs. Results from a phase II international multicenter clinical trial demonstrated a complete response rate of 61% in patients with refractory or relapsed bone and/or bone marrow disease (not involving soft tissue). In addition to the trial patients, 55 patients with first complete remission from high-risk neuroblastoma were treated with noxituzumab injection. The results showed that regardless of whether they received high-dose chemotherapy and autologous transplantation, the three-year survival rate was 92%. Nineteen of the 27 patients who received nascituzumab injection tested negative for MRD. Results were further improved when the monoclonal antibody was combined with granulocyte-monocyte colony-stimulating factor (GM-CSF) to increase the effector activity of macrophages and neutrophils.

It is understood that noxituzumab injection has been approved in China, but it has not been included in medical insurance. Its price is still unclear and the purchase method is difficult. The original drug of Naxituzumab injection marketed overseas is very expensive, and the price may fluctuate due to exchange rates. For more drug information and specific prices, please consult a medical consultant.